

SAFETY DATA SHEET

Genentech
A Member of the Roche Group

OCREVUS Vials 300 mg/10ml

Version
1.0

Revision Date:
06/14/2025

Date of last issue: -
Date of first issue: 06/14/2025

SECTION 1. IDENTIFICATION

Product name : OCREVUS Vials 300 mg/10ml

Product code : RO496-4913/F07-00

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way
South San Francisco, CA 94080
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ocrelizumab	637334-45-3	3
Trehalose (D+)-, 2H ₂ O	6138-23-4	4
Sodium acetate trihydrate	6131-90-4	0.22
Acetic acid	64-19-7	0.02
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.02
Water	7732-18-5	92

SECTION 4. FIRST AID MEASURES

OCREVUS Vials 300 mg/10mlVersion
1.0Revision Date:
06/14/2025Date of last issue: -
Date of first issue: 06/14/2025

General advice : Do not leave the victim unattended.

If inhaled : If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

In case of skin contact : Wash off with soap and water.

In case of eye contact : Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing

Notes to physician : Treat symptomatically.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : No information available.

Hazardous combustion products : Carbon oxides
Carbon monoxide
Nitrogen oxides (NOx)
Sulfur oxides

Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

OCREVUS Vials 300 mg/10mlVersion
1.0Revision Date:
06/14/2025Date of last issue: -
Date of first issue: 06/14/2025**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Refer to protective measures listed in sections 7 and 8.

Environmental precautions : If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece). Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protect from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Stainless steel, glass, Vials

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ocrelizumab	637334-45-3	IOEL	0.02 mg/m ³	Roche Industrial Hygiene Committee (RIHC)

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and

OCREVUS Vials 300 mg/10mlVersion
1.0Revision Date:
06/14/2025Date of last issue: -
Date of first issue: 06/14/2025

use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material

In case of contact through splashing:

Break through time
Glove thickness: Nitrile rubber
: > 30 min
: > 0.11 mm

Material

In case of full contact:

Break through time
Glove thickness: butyl-rubber
: > 480 min
: > 0.4 mm

Remarks

: Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection

: Safety glasses

Skin and body protection

: Protective suit

Hygiene measures

: General industrial hygiene practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution, Clear liquid, sterile

Color : colorless

Odor : No data available

Odor Threshold : No data available

pH : 5.3

Melting point/ range : No data available

Boiling point/boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Self-ignition : Not applicable

OCREVUS Vials 300 mg/10ml

Version 1.0 Revision Date: 06/14/2025 Date of last issue: -
Date of first issue: 06/14/2025

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : completely miscible

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Explosive properties : No data available

Oxidizing properties : No data available

Particle characteristics

Particle Size Distribution : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No data available
No dangerous reaction known under conditions of normal use.

Chemical stability : Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created
Stable under normal conditions.

Possibility of hazardous reactions : Stable under recommended storage conditions.
No hazards to be specially mentioned.

OCREVUS Vials 300 mg/10ml

Version 1.0 Revision Date: 06/14/2025 Date of last issue: - Date of first issue: 06/14/2025

Conditions to avoid : No data available

Incompatible materials : No data available

Not applicable

Hazardous decomposition products : No data available

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified due to lack of data.

Components:**Trehalose (D+)-, 2H2O:**

Acute oral toxicity : LD50 (Rat): 16,000 mg/kg

Ocrelizumab:

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : LD0 (cynomolgus monkey): 100 mg/kg
Application Route: i.v.
GLP: yes

Skin corrosion/irritation

Not classified due to lack of data.

Serious eye damage/eye irritation

Not classified due to lack of data.

Respiratory or skin sensitization**Skin sensitization**

Not classified due to lack of data.

Respiratory sensitization

Not classified due to lack of data.

Germ cell mutagenicity

Not classified due to lack of data.

Carcinogenicity

Not classified due to lack of data.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

SAFETY DATA SHEET

Genentech
A Member of the Roche Group

OCREVUS Vials 300 mg/10ml

Version
1.0

Revision Date:
06/14/2025

Date of last issue: -
Date of first issue: 06/14/2025

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified due to lack of data.

Components:

Ocrelizumab:

Effects on fetal development : Species: cynomolgus monkey
Application Route: i.v.
Dose: 100 milligram per kilogram
Result: No teratogenic effects., No embryotoxic effects.

STOT-single exposure

Not classified due to lack of data.

STOT-repeated exposure

Not classified due to lack of data.

Aspiration toxicity

Not classified due to lack of data.

Further information

Product:

Remarks : No data available

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Trehalose (D+)-, 2H2O:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Test Type: static test

Toxicity to fish (Chronic toxicity) : NOEC (Danio rerio (zebra fish)): 100 mg/l
Exposure time: 96 d

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Ocrelizumab:

OCREVUS Vials 300 mg/10ml
Version
1.0Revision Date:
06/14/2025Date of last issue: -
Date of first issue: 06/14/2025

Toxicity to fish : LC50 (Poecilia reticulata (guppy)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203
 GLP: yes
 Remarks: nominal concentration

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h
 Test Type: Immobilization
 Method: OECD Test Guideline 202
 GLP: yes
 Remarks: nominal concentration

NOEC (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h
 Test Type: Immobilization
 Method: OECD Test Guideline 202
 GLP: yes
 Remarks: nominal concentration

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
 Exposure time: 72 h
 Test Type: Growth inhibition
 Method: OECD Test Guideline 201
 GLP: yes
 Remarks: nominal concentration

EyC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
 Exposure time: 72 h
 Test Type: Growth inhibition
 Method: OECD Test Guideline 201
 GLP: yes
 Remarks: nominal concentration

Persistence and degradability
Components:
Trehalose (D+)-, 2H2O:

Biodegradability : aerobic
 Inoculum: activated sludge, non-adapted
 Biochemical oxygen demand
 Result: Readily biodegradable.
 Biodegradation: 73 %
 Method: OECD Test Guideline 301A
 Remarks: The 10 day time window criterion is not fulfilled.

aerobic
 Inoculum: activated sludge, non-adapted
 Dissolved organic carbon (DOC)
 Result: Readily biodegradable.
 Biodegradation: 98 %
 Method: OECD Test Guideline 301A

OCREVUS Vials 300 mg/10mlVersion
1.0Revision Date:
06/14/2025Date of last issue: -
Date of first issue: 06/14/2025**Ocrelizumab:**

Biodegradability : aerobic
Theoretical oxygen demand
Result: Readily biodegradable.
Biodegradation: 93 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
GLP: yes

Bioaccumulative potential**Components:****Trehalose (D+)-, 2H2O:**

Partition coefficient: n-octanol/water : Remarks: No data available

Ocrelizumab:

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

Other adverse effects**Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

OCREVUS Vials 300 mg/10mlVersion
1.0Revision Date:
06/14/2025Date of last issue: -
Date of first issue: 06/14/2025**IATA-DGR**

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Special precautions for user

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

SECTION 15. REGULATORY INFORMATION**CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
SARA 311/312 Hazards	: No SARA Hazards	

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMi Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

Acetic acid 64-19-7 >= 0 - < 0.1 %

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Acetic acid 64-19-7 >= 0 - < 0.1 %

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations**Massachusetts Right To Know****Pennsylvania Right To Know**

SAFETY DATA SHEET

Genentech
A Member of the Roche Group

OCREVUS Vials 300 mg/10ml

Version
1.0

Revision Date:
06/14/2025

Date of last issue: -
Date of first issue: 06/14/2025

Water	7732-18-5
Trehalose (D+)-, 2H ₂ O	6138-23-4
Ocrelizumab	637334-45-3
Acetic acid	64-19-7

Maine Chemicals of High Concern

Vermont Chemicals of High Concern

Washington Chemicals of High Concern

The ingredients of this product are reported in the following inventories:

AIIC	: Not in compliance with the inventory
DSL	: This product contains the following components that are not on the Canadian DSL nor NDSL. Ocrelizumab
NZIoC	: On the inventory, or in compliance with the inventory
ENCS	: Not in compliance with the inventory
ISHL	: Not in compliance with the inventory
KECI	: Not in compliance with the inventory
PICCS	: Not in compliance with the inventory
IECSC	: Not in compliance with the inventory
TCSI	: Not in compliance with the inventory
TSCA	: Product contains substance(s) not listed on TSCA inventory.
TECI	: Not in compliance with the inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.


SECTION 16. OTHER INFORMATION

Further information

OCREVUS Vials 300 mg/10ml

Version
1.0Revision Date:
06/14/2025Date of last issue: -
Date of first issue: 06/14/2025

NFPA 704:



HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoc - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United

SAFETY DATA SHEET

Genentech
A Member of the Roche Group

OCREVUS Vials 300 mg/10ml

Version
1.0

Revision Date:
06/14/2025

Date of last issue: -
Date of first issue: 06/14/2025

Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods;
vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 06/14/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404